About Us

Learn more about InSitu Biologics

InSitu Biologics

InSitu Biologics, LLC is an emerging biotech company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.

For Media & Press

Please contact

Katie M.

For Investors

Please contact


Pre-Clinical Results

As compared to EXPAREL (Pacira, Inc.), the industry leading post-operative pain treatment.

300% Longer

Initial animal study revealed AnestaGel™ lasted up to 300% longer

8x More Capacity

AnestaGel™ carried 8 times more payload

72+ Hours

AnestaGel™ had full nerve block beyond 72 hours

See our study at the Journal of Pain Research

Investment Opportunity

InSitu Biologics is hosting a Regulation A+ offering to a limited number of investors.

Why Invest

  • Non-opioid painkiller – pre-clinical stage
  • Lasts up to 300% longer than leading competitor*
  • 22 U.S. Patents
  • Invest with your IRA

The Offering

Max Raise
Min. Per Investor
Current Share Price

Competitor Market Size


  • 2016

    Filed additional patent(s)

    White Paper published

    Completed maximum dosing study with no toxicity

    Presented at PODD-Boston

  • 2017

    Completed first GLP study

    Proved more pain relief compared to Exparel in pre-clinical study

    GLP publication accepted

    Raised over $400k

  • 2018

    Completed Financial Audit
    Converted all debt
    Filed $10,000,000 RegA+ Offering

    Launch RegA+ Offering
    Announce GLP Paper by Hutchins & Taylor

    Begin Phase 1 program manufacturing

    Announce final GLP Study results

  • 2019

    SEC valuation incorporating Animal Care Market opportunity

    Submit GLP results for Peer-Review

    FDA Pre-IND meeting

    Expect approval for Phase 1 Clinical Study of AnestaGel

Executive Team

James Segermark


Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.

Bill Taylor

Chief Scientist

Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.

Get in Touch

For media or investor inquires please contact
Contact Us